Latest Period
Q2 2026
Security Snapshot
Hemab Therapeutics Holdings, Inc. - Common Stock, par value $0.001 per share (COAG) Institutional Ownership
CUSIP: 423494103
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
55
Shares (Excl. Options)
36,183,003
Price
$36.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- COAG on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 36,183,003
- Total 13F value
- $1,329,008,078
- Portfolio coverage rank
- 0%
- Share change
- +36,183,003
- Value change
- +$1,329,008,078
- Number of holders
- 55
- Shares outstanding
- 46,717,224
- SEC-reported price per share
- $39.51
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- COAG - Hemab Therapeutics Holdings, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 423494103.
- 55 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 55 institutions filings for Q2 2026.
Security key
423494103
Latest holder period
Q2 2026
13F holders
55
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
COAG full holder history
Hemab Therapeutics Holdings, Inc. SEC filings
Hemab Therapeutics Holdings, Inc. company facts
Hemab Therapeutics Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 423494103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
COAG
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 9% | $165,173,530 | 4,180,550 | Novo Holdings A/S | 30 Jun 2026 | |||
| FMR LLC | 7.9% | $146,101,540 | 3,697,837 | FMR LLC | 30 Jun 2026 | |||
| Capital International Investors | 7.7% | $142,389,141 | 3,603,876 | Capital International Investors | 30 Jun 2026 | |||
| Avoro Capital Advisors LLC | 7.1% | $130,313,304 | 3,298,236 | Behzad Aghazadeh | 30 Jun 2026 | |||
| Sofinnova Crossover II S.L.P. | 5.4% | $99,217,986 | 2,511,212 | Sofinnova Crossover II SLP | 30 Jun 2026 | |||
| Invus Global Management, LLC | 5.1% | $93,489,945 | 2,366,235 | Raymond Debbane | 03 Aug 2026 |
As of 30 Jun 2026, 55 institutional investors reported holding 36,183,003 shares of Hemab Therapeutics Holdings, Inc. - Common Stock, par value $0.001 per share (COAG). This represents 77% of the company’s total 46,717,224 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
76%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17% | 7,808,627 | 2.5% | $286,810,870 | |
| NOVO HOLDINGS A/S | 8.9% | 4,180,550 | 9% | $153,551,602 | |
| FMR LLC | 7.9% | 3,697,837 | 0.01% | $135,821,553 | |
| Capital International Investors | 7.7% | 3,603,876 | 0.03% | $132,370,365 | |
| Deep Track Capital, LP | 7.7% | 3,602,093 | 1.9% | $132,304,876 | |
| Siren, L.L.C. | 4.5% | 2,086,834 | 1.6% | $76,649,413 | |
| Avoro Capital Advisors LLC | 4.1% | 1,925,150 | 0.63% | $70,710,760 | |
| Bain Capital Life Sciences Investors, LLC | 3.5% | 1,650,000 | 3.6% | $60,604,500 | |
| JPMORGAN CHASE & CO | 2.5% | 1,152,420 | 0% | $42,328,387 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 780,758 | 0% | $28,677,241 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 746,040 | 0% | $27,404,000 | |
| Driehaus Capital Management LLC | 1.5% | 715,791 | 0.15% | $26,291,003 | |
| Rock Springs Capital Management LP | 1.2% | 575,432 | 1% | $21,135,617 | |
| Bellevue Group AG | 1.2% | 550,000 | 0.43% | $20,201,500 | |
| CITADEL ADVISORS LLC | 1.1% | 523,450 | 0.01% | $19,226,319 | |
| BlackRock, Inc. | 0.61% | 283,833 | 0% | $10,425,186 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.59% | 275,000 | 0.11% | $10,100,750 | |
| ExodusPoint Capital Management, LP | 0.47% | 218,287 | 0.07% | $8,017,682 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.45% | 211,798 | 0% | $7,783,580 | |
| BRAIDWELL LP | 0.34% | 160,000 | 0.22% | $5,876,800 | |
| MARSHALL WACE, LLP | 0.33% | 154,674 | 0% | $5,681,176 | |
| Woodline Partners LP | 0.32% | 150,040 | 0.02% | $5,510,969 | |
| Affinity Asset Advisors, LLC | 0.3% | 138,030 | 0.25% | $5,069,842 | |
| Ensign Peak Advisors, Inc | 0.25% | 115,394 | 0.01% | $4,238,422 | |
| VANGUARD FIDUCIARY TRUST CO | 0.24% | 112,499 | 0% | $4,132,088 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 36,183,003 | $1,329,008,078 | +$1,329,008,078 | $36.73 | 55 |